Radiotracers for Nuclear Imaging of Reactive Oxygen Species: Advances Made So Far

Huang, Lumei; Li, Zijing; Zhang, Xianzhong

doi:10.1021/acs.bioconjchem.2c00050

Cited by 5 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular imaging is defined as the visualization, characterization, and quantification of biological processes in intact living subjects using specific imaging probes [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. Nowadays, molecular imaging technologies provide insights into biological events, pathology, and the mechanisms of diseases; thus, they play an important role in various fields of neuroscience, cardiology, gene therapy, oncology, and so on [ 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Nguyen

Kim

2023

Pharmaceutics

View full text Add to dashboard Cite

Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for the detection and therapy of tumor hypoxia. Nitroimidazoles are bioreducible moieties that can be selectively reduced under hypoxic conditions covalently bind to intracellular macromolecules, and are trapped within hypoxic cells and tissues. Recently, there has been a strong motivation to develop PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazole moieties for the visualization and treatment of hypoxic tumors. In this review, we summarize the development of some novel PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazoles, as well as their physicochemical properties, in vitro cellular uptake values, in vivo biodistribution, and PET/SPECT imaging results.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Nguyen

Kim

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Molecular imaging technologies have emerged as powerful tools that offer valuable insights into biological events, disease pathology, and underlying mechanisms. As a result, they have become increasingly indispensable in diverse fields such as neuroscience, drug therapy assessment, oncology, and numerous others [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Advances of 68Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors

Nguyen

Kim

2023

IJMS

View full text Add to dashboard Cite

Positron emission tomography (PET) is a noninvasive molecular imaging method extensively applied in the detection and treatment of various diseases. Hypoxia is a common phenomenon found in most solid tumors. Nitroimidazole is a group of bioreducible pharmacophores that selectively accumulate in hypoxic regions of the body. Over the past few decades, many scientists have reported the use of radiopharmaceuticals containing nitroimidazole for the detection of hypoxic tumors. Gallium-68, a positron-emitting radioisotope, has a favorable half-life time of 68 min and can be conveniently produced by 68Ge/68Ga generators. Recently, there has been significant progress in the preparation of novel 68Ga-labeled complexes bearing nitroimidazole moieties for the diagnosis of hypoxia. This review provides a comprehensive overview of the current status of developing 68Ga-labeled radiopharmaceuticals with nitroimidazole moieties, their pharmacokinetics, and in vitro and in vivo studies, as well as PET imaging studies for hypoxic tumors.

show abstract

“…Excessive production of ROS can be consequence of many diseases, including cancer, cardiovascular, and neurodegenerative diseases. Quantification of ROS levels in the body by PET imaging could serve as an early cancer diagnosis/screening tool, and add value to prognosis assessment [ 26 , 27 ]. A recent in vivo study used [ 11 C]ascorbic acid to define the sodium ion (Na + )-dependent transport mechanisms of ascorbic acid [ 28 , 29 ] and its redox partner dehydroascorbic acid (DHA) in mouse brains and confirmed its oxidative sensitivity [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

[18F]KS1, a novel ascorbate-based ligand images ROS in tumor models of rodents and nonhuman primates

Damuka¹,

Bashetti²,

Mintz³

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Radiotracers for Nuclear Imaging of Reactive Oxygen Species: Advances Made So Far

Cited by 5 publications

References 82 publications

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Recent Advances of 68Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors

[18F]KS1, a novel ascorbate-based ligand images ROS in tumor models of rodents and nonhuman primates

Contact Info

Product

Resources

About